# Madrigal Pharmaceuticals Inc. (MDGL) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $396.32, market value $9.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Madrigal Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 1.00**. A PEG of 1.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 7.1×**. Each dollar of revenue is priced at 7.1×.
- **Price / book: 14.6×**. The shares trade at 14.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.3%** (5-yr avg -6.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -25.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -30.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -47.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -34.3%**. Return on all capital, debt included, is -34.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -25.8%**. Each dollar of assets produces -25.8% of profit.

## Growth
- **Revenue growth (1 yr): 432.1%**. Revenue grew 432.1% over the last year.
- **EPS growth (1 yr): 41.3%**. Earnings per share rose 41.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.56**. Debt is 0.56 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Madrigal Pharmaceuticals Inc. holds more cash than debt.
- **Current ratio: 4.01** (quick 4.01). Current assets cover the next year's liabilities 4.01 times.
- **Altman Z-score: 9.90**. A Z-score of 9.90 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Madrigal Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (18 analysts). 18 analysts cover Madrigal Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $685.22 (+73% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 2.9%** (YTD -26.0%, 3-mo -10.5%). The shares are up 2.9% over twelve months including dividends.
- **From 52-week high: -35.6%** (2.3% above the low). Trading 36% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 30**. An RSI of 30 is neutral.
- **Beta (1 yr): 0.33** (volatility 43%). Beta of 0.33 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MDGL · Page: https://foliofundamentals.com/stocks/mdgl

Not investment advice.